![Ali Raza](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ali Raza
Profile
Ali Raza served as President & Director at Sosei Co. Ltd., Head-Clinical Sciences Department at AstraZeneca PLC, and President-AeroLEF Division at YM BioSciences, Inc. He obtained an undergraduate degree from The University of Manchester and a doctorate degree from the University of London.
Former positions of Ali Raza
Companies | Position | End |
---|---|---|
Sosei Co. Ltd.
![]() Sosei Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sosei Group Corp., Sosei Co. Ltd. is a world-leader in GPCR medicine design and development. The company is based in Tokyo, Japan. The Japanese company obtains and maintains intellectual property rights to protect its innovations and technologies. | President | - |
ASTRAZENECA PLC | Chief Tech/Sci/R&D Officer | - |
YM BioSciences, Inc.
![]() YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
Training of Ali Raza
The University of Manchester | Undergraduate Degree |
University of London | Doctorate Degree |
Experiences
Positions held
Linked companies
Listed companies | 1 |
---|---|
ASTRAZENECA PLC | Health Technology |
Private companies | 2 |
---|---|
YM BioSciences, Inc.
![]() YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Sosei Co. Ltd.
![]() Sosei Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sosei Group Corp., Sosei Co. Ltd. is a world-leader in GPCR medicine design and development. The company is based in Tokyo, Japan. The Japanese company obtains and maintains intellectual property rights to protect its innovations and technologies. | Commercial Services |
- Stock Market
- Insiders
- Ali Raza